Work

Unraveling BOLD-100 synergistic potential in pleural mesothelioma treatment: an in vitro study

Year: 2025

Type: article

Abstract: Pleural mesothelioma (PM) is a rare cancer affecting the pleural layer on the body's serosal surfaces. Exposure to asbestos fibers, a naturally occurring fibrous material with insulating characteristics, contributes to PM's prevalence. PM has a long latency period, making major surgery ineffective and necessitating systemic treatment. Despite the progress of mesothelioma treatment, the median survival is very poor; so, there is a strong need to explore new therapeutic approaches. This study explores the use of BOLD-100, a novel therapeutic drug that targets GRP78, a protein overexpressed in PM cells. BOLD-100, a ruthenium-based small molecule therapeutic drug, is being investigated for the treatment of advanced gastrointestinal malignancies in conjunction with chemotherapy. Our aim is to investigate cellular responses of several PM cell lines to a regimen that includes BOLD-100 in addition to other commonly used treatments. BOLD-100 is a ruthenium-based anticancer therapeutic.

Source: Investigational New Drugs

DOI: 10.1007/s10637-025-01540-9

Authors: Gregorio Bonsignore, Elia Ranzato, Simona Martinotti

Institutions: Università degli Studi del Piemonte Orientale “Amedeo Avogadro”, Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo

Language: English

Topic: Occupational and environmental lung diseases

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,690